Market Newsdesk

MONTREAL, Jan. 04, 2021 (GLOBE NEWSWIRE) — For all those who are looking to take a positive step for their health and the planet in 2021, here’s a new habit that won’t be hard to keep! Just in time for New Year’s resolutions, Savvy Pantry has launched a brand new subscription box to make healthy and plant-based eating easier than ever.

Subscribers will receive a box containing a selection of Savvy Pantry’s signature gourmet ready-to-cook vegan dishes, a featured monthly seasoning mix and recipes for using the mix in creative ways, as well as samples of new Savvy Pantry products. Boxes start at $36 per month, and subscriptions can be paused or cancelled anytime.

“Our goal is to help Canadians eat better while simplifying their lives, and this launch hits the mark,” said Savvy Pantry’s founder, Daphne Ferguson. “Not only does the subscription model take the hassle out of re-ordering, but our new seasoning mixes and recipe blog make it easier than ever to whip up delicious and healthy home-cooked meals on even the busiest of days.”

With Canadians eating at home more than ever and looking increasingly for plant-based meal ideas, Savvy Pantry’s ready-to-cook vegan soups and bowls respond to growing trends that are here to stay. At a cost-per-serving varying from $1.40 to $1.80, they also offer an incredibly affordable alternative to meal kits and takeaway.

Boxes can be ordered online at www.savvypantry.com.

About Savvy Pantry:

Founded in Montreal in 2019, Savvy Pantry’s mission is to make healthy, plant-based eating easy and delicious. The company produces a line of all-natural mixtures for vegan soups and sides to take the hassle out of meal preparation. Most products require only the addition of water and cook in 30 minutes or less. Savvy Pantry’s products are proudly made in Quebec and are available on a variety of online grocery platforms as well as a growing number of retail locations.

BOSTON and DURHAM, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) — Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced the appointment of Clare Grace, Ph.D., as the company’s first Chief Patient Officer. The appointment reflects the role of the patient as central to the company’s mission of keeping patients at the heart of all clinical trial activity.

The appointment of a Chief Patient Officer is a first for a top-tier CRO, further demonstrating Parexel’s commitment to elevate the patient perspective so that their unique needs can be used to shape the conduct of future clinical studies.

“Patients are at the heart of everything we do,” said Sy Pretorius, MD, Chief Medical and Scientific Officer at Parexel. “Clare’s proven track record of delivering innovative patient and site engagement programs make her the perfect candidate to lead our patient-focused mission. We are pleased to welcome her to Parexel as we further evolve our support for patients and investigative sites worldwide.”

“I am thrilled to join Parexel and to continue to champion the company’s patient focus to ultimately improve clinical trials and accelerate the delivery of new therapies for patients around the world,” said Dr. Grace. “I look forward to working closely with our sites and technology partners to improve the patient experience and to further infuse the patient perspective across all studies and further enhance our ability to deliver innovative clinical trial solutions that meet our customers’ needs.”

With more than 20 years of experience in the CRO and biopharmaceutical industries, Dr. Grace was recognized in 2018 by PharmaVoice as one of the top 100 most inspirational leaders in the pharmaceutical industry. She earned a doctorate in Molecular Oncology from the University of Manchester Institute of Science and Technology and a bachelor’s degree in applied biochemistry from Liverpool John Moores University, both in England. Dr. Grace is active in several global and national-level advisory groups, including the Society for Clinical Research Sites (SCRS) and the SCRS Leadership Council.

As Chief Patient Officer for Parexel, Dr. Grace will lead global patient advocacy and site efforts, including patient engagement strategies and efforts to enhance clinical trial diversity as well as new, innovative approaches to help teams and customers work more effectively with investigative sites. Most recently she served as Vice President, Site & Patient Access at Syneos Health, formerly INC Research, where she oversaw all departments responsible for patient engagement, feasibility, site identification, strategic site relations and investigator payments. Her experience also includes senior-level patient and site-focused leadership roles with PPD, Astra Zeneca and Antisoma.

About Parexel

Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life science and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. Parexel was named “Best Contract Research Organization” in December 2020 by an independent panel for Informa Pharma Intelligence. For more information, visit our website and follow us on LinkedIn, Twitter and Instagram.

CONTACT:

Parexel
Lori Dorer
+1 513 496 8121
[email protected]

W2O

Lindsay LeCain
+1 508 259 9521
[email protected]

DENVER, Jan. 04, 2021 (GLOBE NEWSWIRE) — Bow River Capital, a Denver-based private alternative asset management firm, is pleased to announce the launch of the Bow River Capital Evergreen Fund (“the Fund”) which is designed to expand private equity access to a broader set of investors.

In a single investment the Fund presents a unique opportunity to access institutional quality private equity investments with broad exposure, low investment minimums and immediate investment exposure.

“We are excited to launch what we believe is a transformative solution for the private equity market,” said Jeremy Held, Managing Director at Bow River. “The Evergreen Fund brings our specialized knowledge and private market experience to a wider investor base, many of whom historically have had difficulty accessing the asset class.”

According to Cambridge Associates, private equity has been one of the best performing asset classes for decades.¹ However, due to high investment minimums and long lock up periods, widespread access to private equity has been limited, especially among individual investors.

The Fund will accept $50,000 minimum subscriptions on a monthly basis from accredited investors and unlike traditional private equity funds that invest capital over a period of months or years, subscriptions into the Evergreen Fund are immediately invested. Beyond providing a solution for individuals who don’t have access to private equity, the evergreen nature of the Fund provides investors with a better tool to customize their overall exposure to the asset class.

“Our investor base has increasingly been looking for a complementary solution that leverages our private equity expertise in a vehicle with more liquidity and diversification than a typical private equity fund,” said Bow River Capital President Richard Wham. The Fund intends to offer periodic liquidity to its investors on a quarterly basis.

Bow River Capital has developed a successful private equity track record with nearly two decades of experience underwriting and investing in private companies. In addition, Bow River’s investment team has extensive experience managing both evergreen private equity strategies and registered funds. To complement Bow River’s team, the Fund has partnered with Aksia, a leading global alternatives firm with over $160 billion in client-advised assets and institutional-quality sourcing and research capabilities. 

The Fund’s concept has resonated with investors. After launching as a private fund in May 2020 the Fund has amassed approximately $90 million in investor commitments and has invested $70 million across 18 private equity and private credit transactions. The private fund converted to a registered fund on December 31, 2020 to expand its universe of eligible investors.

“The significant interest we have seen to date in the Evergreen Fund confirms our belief that the time is right for this type of investment solution” said Wham. “We believe the Fund’s combination of access to private equity investments – along with the shareholder-friendly features of a registered fund – will continue to attract interest from investors and the advisors who serve them.”

An offer can only be made by the prospectus and only in jurisdictions in which such an offer would be lawful. The prospectus contains important information concerning risk factors and other material aspects of the Fund to carefully consider, and must be read carefully before a decision to invest is made.

Please email

[email protected]

or contact your Financial Advisor to obtain a copy of the prospectus.

Any person subscribing for an investment must be able to bear the risks involved and must meet the suitability requirements of the Fund. Investors could lose all or a substantial amount of their investment. No assurance can be given that the Fund’s investment objectives will be achieved. The Fund is speculative and involves a substantial degree of risk. The Fund is a closed-end, non-diversified management investment company that will make periodic repurchase offers for its securities, and is highly illiquid. There is no secondary market for investors’ interests and none is expected to develop. There are certain restrictions on transferring interests. Fees and expenses will offset the Fund’s trading profits. The Fund is subject to conflicts of interest. Other risks include those related to equity securities, fixed income securities, high-yield/high risk bonds, listed private equity, listed infrastructure securities, foreign securities, derivative instruments, leverage, capital calls, investment manager risk, as well as those related to general economic and market conditions, all of which may present significant risks. Please see the prospectus for more information on these and other risks.

About Bow River Capital

Bow River Capital is a private alternative asset management company based in Denver, Colorado, focused on investing in the lower middle market in three asset classes, including private equity, real estate, and software growth equity. For more information about Bow River, please visit www.bowrivercapital.com.  

Distributor: Foreside Fund Distributors, LLC

¹ Cambridge US Private Equity Benchmark Book 9/30/19, Bloomberg.

Orlando, Florida, Jan. 04, 2021 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of influencer marketing technology, data, and services for leading brands today announced the appointment of Katie Mellor as the company’s new Head of Client Services. Mellor will join IZEA’s Senior Staff and be responsible for leading a team of Campaign Management professionals and Creator Ecosystem consultants that interact with IZEA clients daily to drive strategic growth.

Mellor joins IZEA after having spent nearly two decades in the marketing and advertising industry, focusing on brand marketing and customer experiences. Most recently, she served as Group Account Director at Latcha+Associates, overseeing the agency’s Audi and Volkswagen accounts. Prior, Katie held a variety of leadership positions across WPP – including Vice President, Account Director at GTB and various client oversight roles at Ogilvy. A native of Detroit, Mellor received her Bachelor’s degree from the College of Communications, Arts, & Sciences at Michigan State University.

“Katie brings a wealth of experience in building and growing high performing teams that understand how to make brands both highly compelling and enormously successful. She also comes to us with a deep knowledge of integrated advertising strategy, of which Influencer Marketing is critical component for modern brand-builders,” said Ryan Schram, Chief Operating Officer of IZEA. “We are incredibly fortunate to have her joining Team IZEA.”

About IZEA Worldwide, Inc.

IZEA Worldwide, Inc. (“IZEA”) is a marketing technology company providing software and professional services that enable brands to collaborate and transact with the full spectrum of today’s top social influencers and content creators. The company serves as a champion for the growing Creator Economy, enabling individuals to monetize their content, creativity, and influence. IZEA launched the industry’s first-ever influencer marketing platform in 2006 and has since facilitated nearly 4 million transactions between online buyers and sellers. Leading brands and agencies partner with IZEA to increase digital engagement, diversify brand voice, scale content production, and drive measurable return on investment.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking  terms such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” or other comparable terms. Examples of forward-looking statements include, among others, statements we make regarding expectations of sales activity, revenue and margins based on bookings, plans to increase the size of our sales team, the financial impact of investments in our software business, and continuation of new IZEAx customers and their effect on future sales.

Forward-looking statements involve inherent risks and uncertainties, which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors, including, among others, the following: competitive conditions in the content and social sponsorship segment in which IZEA operates; failure to popularize one or more of the marketplace platforms of IZEA; changing economic conditions that are less favorable than expected; and other risks and uncertainties described in IZEA’s periodic reports filed with the Securities and Exchange Commission.  IZEA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Attachment

• Katie Mellor joins IZEA as Vice President, Client Services

ESSEX, England, Jan. 04, 2021 (GLOBE NEWSWIRE) — Since the first recorded COVID-19 case appeared in the Hubei Province of China over one year ago, the world has been caught in a flurry of breaking news, distressing headlines, startling statistics and auspicious scientific breakthroughs. As vaccines begin making their debut, people may gain a false sense of hope for a pre-pandemic lifestyle that feels ever distant. However, as author and practicing physician Ken Menon explains in his book, “Lockdown 2020: Covid-19 in the UK,” the aftershock of this pandemic will be felt for years to come.

“Lockdown 2020” is an eye-opening, educational examination of the short- and long-term impact of the coronavirus pandemic. Menon chronicles the events leading up to the virus’ outbreak and implementation of mandatory lockdown in the United Kingdom, providing a thorough analysis of the failed responsibility by political and healthcare leaders to plan and prepare for a public health crisis of such magnitude. Comparing the UK’s response to that of countries that were successful in minimizing their infection rate and death count like South Korea and New Zealand, he pinpoints both the successes and missteps made in addressing, containing and tracking the virus’ spread.

Moving past the initial consequences of the outbreak and subsequent lockdown, Menon dives into the deeper implications it poses for areas like education, finance, economic welfare and public health and safety. Calling attention to issues such as domestic violence, child abuse, care for other life-threatening medical conditions, unemployment and social inequality that have been exacerbated by the safety measures put in place, he demonstrates how unreadiness and delayed response potentially resulted in more coronavirus deaths and endangered the lives of millions.

Through his analysis, Menon seeks to inform people of the several types of coronaviruses that occur in nature and the threat they pose to human health and safety. By raising awareness that COVID-19 is not an anomaly, he hopes to prepare readers for future crises and emphasize the role every person plays in reducing transmission and protecting others’ right to good health.

“We’re all in this together,” said Menon. “My goal with ‘Lockdown 2020’ is to help people understand the need for lockdown and how they can help themselves and their communities reduce transmission of viruses by taking care of their personal health and complying with safety protocol. We need to learn from this pandemic and resolve to do better before the next crisis.”

“Lockdown 2020: Covid-19 in the UK”
By Ken Menon
ISBN: 9781665580373 (softcover); 9781665580380 (hardcover); 9781665580366 (electronic)
Available from Amazon, Barnes & Noble and AuthorHouse

About the author
Ken Menon is a physician living and practicing in the United Kingdom. “Lockdown 2020: Covid-19 in the UK” is his first book.

AuthorHouseUK, an Author Solutions, Inc. self-publishing imprint, is a leading provider of book publishing, marketing, and bookselling services for authors around the globe and offers the industry’s only suite of Hollywood book-to-film services. Committed to providing the highest level of customer service, AuthorHouse assigns each author personal publishing and marketing consultants who provide guidance throughout the process. Headquartered in Bloomington, Indiana, AuthorHouse celebrates over 23 years of service to authors. For more information or to publish a book visit authorhouse.co.uk or call 0800 047 8203.

Attachment

• 815043HighRes